EPISURF MEDICAL AB (PUBL) PUBLISHES PROSPECTUS
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONG KONG, SWITZERLAND, SINGAPORE OR NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.
Episurf Medical AB (publ) ("Episurf") today publishes a prospectus since the shares of series B in Episurf which were issued by way of a resolution of the general meeting held on 7 December 2018 in accordance with previous announcements shall be admitted to trading on the regulated market Nasdaq Stockholm, where Episurf's shares of series B are currently admitted to trading. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Episurf's website, www.episurf.com and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.
The shares will be admitted to trading on Nasdaq Stockholm as soon as they have been registered with the Swedish Companies Registration Office. Episurf's shares of series B are currently traded on Nasdaq Stockholm under the ticker symbol (EPIS B) and ISIN-code (SE0003491562).
Stockholm on 19 December 2018
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication at 17.35 CET on 19 December 2018.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipient of this press release is responsible for using the information in this press release in accordance with applicable law in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.
These materials may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into the United States. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States absent (i) registration under the U.S. Securities Act of 1933, as amended (the "Securities Act") or (ii) an available exemption from registration under the Securities Act. The securities mentioned herein have not been, and will not be, registered under the Securities Act and will not be offered to the public in the United States
The information in this press release may not be announced, published or distributed to Canada, Australia, South Africa, Japan, Hong Kong, Switzerland, Singapore or New Zealand or in any other jurisdiction where the announcement, publication or distribution of this press release would not comply with applicable laws and regulations.
This press release is not a prospectus for the purposes of Directive 2003/71/EC as amended through Directive 2010/73/EU. The Company has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus or other offering document has been or will be prepared in connection with the directed share issue.
Tags: